国产减重降糖创新药为全球代谢疾病治疗提供“中国方案”

Core Insights - The "Masitide Peptide Dreams Series Research Results Seminar" was held in Beijing, announcing that two key Phase III clinical studies of the innovative weight-loss and blood sugar-lowering drug Masitide Peptide were published in the prestigious international journal "Nature" on December 18, 2025, marking the first Phase III clinical research from China in the field of metabolic diseases published since the journal's inception [1][3] Group 1 - The studies, designated DREAMS-1 and DREAMS-2, were entirely based on data from Chinese patients, showing that Masitide Peptide significantly outperformed the control group in both blood sugar reduction and weight loss [3] - The drug demonstrated comprehensive improvement potential for various cardiovascular, liver, and kidney-related metabolic indicators, providing new hope for many type 2 diabetes patients in China [3] - Experts highlighted the need for treatment options that address both blood sugar and weight, as the traditional approach of solely controlling blood sugar is insufficient for the large population of overweight or obese diabetes patients in China [3][5] Group 2 - The design of the new drug targets the "Chinese characteristics" of metabolic disorders, as Chinese patients often exhibit abdominal obesity despite having a lower body mass index compared to Western patients [5] - The drug's dual-target synergistic effect not only aids in blood sugar reduction and weight loss but also enhances energy expenditure and improves liver fat metabolism, aligning with the specific conditions of Chinese patients [3][5] - Masitide Peptide has been approved in China for both diabetes and weight loss indications, with a 9 mg formulation for weight control already accepted by the National Medical Products Administration [5]